Sugi Predict

Sugi Predict / Compounds / SCHEMBL16636945

SCHEMBL16636945

SCHEMBL16636945

Oc1ncnc2cc(Br)c(Cl)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 2/20 0.36
▸ EGFR P00533 4/20 0.34
▸ FBP1 P09467 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ JAK3 P52333 2/20 0.33
▸ MKNK1 Q9BUB5 1/20 0.33
▸ AR P10275 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ RET P07949 3/20 0.31
▸ KIF5B P33176 3/20 0.31
▸ KDR P35968 3/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29697467 1.00 AHR (0.36) AHREGFRFBP1SMN1; SMN2JAK3
SCHEMBL16636937 0.93 CSNK2A1 (0.37) AHREGFRFBP1SMN1; SMN2JAK3
SCHEMBL8813539 0.84 MAPK13 (0.34) EGFRFBP1RETKIF5BKDR
SCHEMBL29612122 0.81 PDE4A (0.44) AHREGFRFBP1SMN1; SMN2MKNK1
SCHEMBL16636989 0.81 PDE4A (0.44) AHREGFRFBP1SMN1; SMN2MKNK1
SCHEMBL21456827 0.78 EGFR (0.37) EGFRJAK3MKNK1RETKIF5B
SCHEMBL28448867 0.76 ESR1 (0.40) EGFRSMN1; SMN2HTTRETKIF5B
SCHEMBL24579692 0.74 AHR (0.32) AHRCSNK2A1
SCHEMBL22028983 0.74 HTT (0.35) AHREGFRHTTKDRCSNK2A1
SCHEMBL20355005 0.74 JAK3 (0.35) EGFRJAK3MKNK1KDM4ERET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240092756-A1 METHODS AND COMPOSITION FOR KRAS MODIFICATIONS DUNAD THERAPEUTICS LTD. (GB) 2024-03-21 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
EP-4247787-A2 METHODS AND COMPOSITION FOR KRAS MODIFICATIONS 2692372 Ontario, Inc. (CA) 2023-09-27 — — EP disclosed
CN-116745264-A Methods and compositions for KRAS modification 2692372安大略公司 2023-09-12 — — CN disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092756-A1 METHODS AND COMPOSITION FOR KRAS MODIFICATIONS KRAS, NRAS, HRAS AHR 2813/4885EGFR 64/4885FBP1 2721/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS AHR 2040/4885EGFR 235/4885FBP1 3202/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS AHR 2688/4885EGFR 262/4885FBP1 2160/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS AHR 2688/4885EGFR 262/4885FBP1 2160/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS AHR 2477/4885EGFR 180/4885FBP1 1443/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS AHR 2477/4885EGFR 180/4885FBP1 1443/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS AHR 2477/4885EGFR 180/4885FBP1 1443/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS AHR 2477/4885EGFR 180/4885FBP1 1443/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS AHR 2385/4885EGFR 16/4885FBP1 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.